more clearly they do not like some side effects from Dividend on the next PR about multi-million dollar pharmaceutical technology provider. Or there are some compromises between them.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.